Logo

ACAD

ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc. • NASDAQ
$25.04 ▲ 0.93% (+0.23)
Market Cap $4.24 B
52w High $26.65
52w Low $13.40
Dividend Yield 0%
P/E 16.15
Volume 563.25K
Outstanding Shares 169.17M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $278.633M ▲ $221.23M ▲ $71.779M ▲ 25.761% ▲ $0.43 ▲ $47.545M ▲
Q2-2025 $264.566M ▲ $211.458M ▲ $26.666M ▲ 10.079% ▲ $0.16 ▲ $35.309M ▲
Q1-2025 $244.317M ▼ $204.635M ▲ $18.987M ▼ 7.771% ▼ $0.11 ▼ $22.241M ▲
Q4-2024 $259.602M ▲ $84.296M ▼ $143.742M ▲ 55.37% ▲ $0.87 ▲ $12.202M ▼
Q3-2024 $250.401M $199.9M $32.765M 13.085% $0.2 $31.644M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $847.019M ▲ $1.331B ▲ $413.499M ▲ $917.272M ▲
Q2-2025 $761.996M ▲ $1.226B ▲ $403.173M ▲ $822.382M ▲
Q1-2025 $681.577M ▼ $1.132B ▼ $367.127M ▼ $765.237M ▲
Q4-2024 $755.993M ▲ $1.188B ▲ $454.963M ▲ $732.793M ▲
Q3-2024 $565.33M $976.868M $399.688M $577.18M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $71.779M ▲ $74.288M ▲ $-79.352M ▼ $9.423M ▼ $4.359M ▼ $73.9M ▼
Q2-2025 $26.666M ▲ $63.956M ▲ $-43.294M ▲ $15.956M ▲ $36.642M ▲ $162.497M ▲
Q1-2025 $18.987M ▼ $20.323M ▼ $-124.049M ▼ $1.838M ▼ $-101.893M ▼ $-78.515M ▼
Q4-2024 $143.742M ▲ $40.381M ▼ $122.15M ▲ $1.969M ▲ $164.44M ▲ $39.928M ▼
Q3-2024 $32.765M $63.246M $-82.457M $268K $-18.985M $63.176M

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily over the past five years, with a clear acceleration recently as the company’s key drugs scale. Gross profitability is strong, meaning the products themselves are attractive after direct costs. Importantly, operating results have moved from meaningful losses to solid profitability in the latest year, showing that the existing commercial base can now support the company’s cost structure. The swing from negative to positive earnings per share marks a major shift in the business profile, though sustainability will depend on continued uptake of current products and the pace of new launches.

Balance Sheet

Balance Sheet The balance sheet looks relatively healthy and stronger than in prior years. Total assets and cash have increased, giving the company more financial flexibility than it had a few years ago. Debt levels are modest compared with the size of the business, and equity has rebuilt as losses have narrowed and then turned into profits. Overall, ACADIA appears less financially pressured than in the past, with a capital structure that supports ongoing investment without looking overextended.

Cash Flow

Cash Flow Cash generation has improved meaningfully. The business used to consume cash from operations, but has recently shifted to producing positive operating cash flow. Free cash flow has followed the same pattern, helped by very light capital spending needs. This means the company is now better able to fund its own development and commercialization efforts from internal resources, rather than relying as heavily on external financing. The key question going forward is whether this positive cash profile can be maintained as R&D and commercial spending evolve.

Competitive Edge

Competitive Edge ACADIA operates in a focused niche within neuroscience and rare diseases, where it has built a meaningful presence. Its drugs for Parkinson’s disease psychosis and Rett syndrome are first-of-their-kind, giving the company strong positioning with specialists and patient groups. The markets it serves are specialized and often lack alternatives, which reinforces its role but also concentrates risk in a small number of products. Competition from off‑label drugs, new approvals, and future gene or targeted therapies remains an ongoing challenge, especially as larger players may enter overlapping spaces.

Innovation and R&D

Innovation and R&D The company’s strategy is heavily driven by innovation in central nervous system disorders and rare diseases, areas where medical need is high but development risk is also significant. It has already shown the ability to bring first‑in‑class therapies to market and is leveraging that expertise into new programs for conditions like Prader‑Willi syndrome and Alzheimer’s-related psychosis. The pipeline is diversified within CNS, but success is not guaranteed and regulatory or trial setbacks could create volatility. Overall, ACADIA’s identity and potential are closely tied to continued R&D productivity and smart selection of niche indications.

Summary

ACADIA has transitioned from a development‑stage, loss‑making biotech toward a more mature commercial company with growing revenues, improving profitability, and a stronger cash and balance sheet position. Its strength lies in specialized CNS and rare disease markets where it holds first‑mover advantages and deep expertise, supported by meaningful ongoing research. At the same time, dependence on a limited number of products, competitive threats, and inherent clinical and regulatory risks in its pipeline are important factors to watch. The story is now a blend of established product execution and the next wave of innovation, rather than a pure early‑stage speculation.

NEWS

November 20, 2025 · 4:05 PM UTC

Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Read more

November 5, 2025 · 4:05 PM UTC

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

Read more

October 28, 2025 · 4:05 PM UTC

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Read more

October 28, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Read more

October 23, 2025 · 11:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Read more